Home Healthcare Healthcare IT Computer Aided Drug Discovery Market

Computer Aided Drug Discovery Market Size, Share & Trends Analysis Report By Offering (Software, Services), By Type (Structure-Based Drug Design, Ligand-Based Drug Design, Sequence-Based Approaches), By Deployment (On-premises, Cloud-based, Hybrid), By End User (Pharmaceutical Companies, Biotechnology Companies, CROs & CDMOs, Research Institutes) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: October 16, 2026 | Author: Debashree Bora | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Computer Aided Drug Discovery Market, By Offering 2025-2034 (USD MILLION/ Units)
    1. Software
    2. Services
  2. Computer Aided Drug Discovery Market, By Type 2025-2034 (USD MILLION/ Units)
    1. Structure-Based Drug Design
    2. Ligand-Based Drug Design
    3. Sequence-Based Approaches
  3. Computer Aided Drug Discovery Market, By Deployment 2025-2034 (USD MILLION/ Units)
    1. On-premises
    2. Cloud-based
    3. Hybrid
  4. Computer Aided Drug Discovery Market, By End User 2025-2034 (USD MILLION/ Units)
    1. Pharmaceutical Companies
    2. Biotechnology Companies
    3. CROs & CDMOs
    4. Research Institutes
  5. Regional Computer Aided Drug Discovery Market
    1. North America
      1. North America Computer Aided Drug Discovery Market By Offering 2025-2034 (USD MILLION/ Units)
        1. Software
        2. Services
      2. North America Computer Aided Drug Discovery Market By Type 2025-2034 (USD MILLION/ Units)
        1. Structure-Based Drug Design
        2. Ligand-Based Drug Design
        3. Sequence-Based Approaches
      3. North America Computer Aided Drug Discovery Market By Deployment 2025-2034 (USD MILLION/ Units)
        1. On-premises
        2. Cloud-based
        3. Hybrid
      4. North America Computer Aided Drug Discovery Market By End User 2025-2034 (USD MILLION/ Units)
        1. Pharmaceutical Companies
        2. Biotechnology Companies
        3. CROs & CDMOs
        4. Research Institutes
      5. U.S.
        1. Software
        2. Services
        3. Structure-Based Drug Design
        4. Ligand-Based Drug Design
        5. Sequence-Based Approaches
        6. On-premises
        7. Cloud-based
        8. Hybrid
        9. Pharmaceutical Companies
        10. Biotechnology Companies
        11. CROs & CDMOs
        12. Research Institutes
      6. Canada
        1. Software
        2. Services
        3. Structure-Based Drug Design
        4. Ligand-Based Drug Design
        5. Sequence-Based Approaches
        6. On-premises
        7. Cloud-based
        8. Hybrid
        9. Pharmaceutical Companies
        10. Biotechnology Companies
        11. CROs & CDMOs
        12. Research Institutes
    2. Europe
      1. Europe Computer Aided Drug Discovery Market By Offering 2025-2034 (USD MILLION/ Units)
        1. Software
        2. Services
      2. Europe Computer Aided Drug Discovery Market By Type 2025-2034 (USD MILLION/ Units)
        1. Structure-Based Drug Design
        2. Ligand-Based Drug Design
        3. Sequence-Based Approaches
      3. Europe Computer Aided Drug Discovery Market By Deployment 2025-2034 (USD MILLION/ Units)
        1. On-premises
        2. Cloud-based
        3. Hybrid
      4. Europe Computer Aided Drug Discovery Market By End User 2025-2034 (USD MILLION/ Units)
        1. Pharmaceutical Companies
        2. Biotechnology Companies
        3. CROs & CDMOs
        4. Research Institutes
      5. U.K.
        1. Software
        2. Services
        3. Structure-Based Drug Design
        4. Ligand-Based Drug Design
        5. Sequence-Based Approaches
        6. On-premises
        7. Cloud-based
        8. Hybrid
        9. Pharmaceutical Companies
        10. Biotechnology Companies
        11. CROs & CDMOs
        12. Research Institutes
      6. Germany
        1. Software
        2. Services
        3. Structure-Based Drug Design
        4. Ligand-Based Drug Design
        5. Sequence-Based Approaches
        6. On-premises
        7. Cloud-based
        8. Hybrid
        9. Pharmaceutical Companies
        10. Biotechnology Companies
        11. CROs & CDMOs
        12. Research Institutes
      7. France
        1. Software
        2. Services
        3. Structure-Based Drug Design
        4. Ligand-Based Drug Design
        5. Sequence-Based Approaches
        6. On-premises
        7. Cloud-based
        8. Hybrid
        9. Pharmaceutical Companies
        10. Biotechnology Companies
        11. CROs & CDMOs
        12. Research Institutes
      8. Spain
        1. Software
        2. Services
        3. Structure-Based Drug Design
        4. Ligand-Based Drug Design
        5. Sequence-Based Approaches
        6. On-premises
        7. Cloud-based
        8. Hybrid
        9. Pharmaceutical Companies
        10. Biotechnology Companies
        11. CROs & CDMOs
        12. Research Institutes
      9. Italy
        1. Software
        2. Services
        3. Structure-Based Drug Design
        4. Ligand-Based Drug Design
        5. Sequence-Based Approaches
        6. On-premises
        7. Cloud-based
        8. Hybrid
        9. Pharmaceutical Companies
        10. Biotechnology Companies
        11. CROs & CDMOs
        12. Research Institutes
      10. Russia
        1. Software
        2. Services
        3. Structure-Based Drug Design
        4. Ligand-Based Drug Design
        5. Sequence-Based Approaches
        6. On-premises
        7. Cloud-based
        8. Hybrid
        9. Pharmaceutical Companies
        10. Biotechnology Companies
        11. CROs & CDMOs
        12. Research Institutes
      11. Nordic
        1. Software
        2. Services
        3. Structure-Based Drug Design
        4. Ligand-Based Drug Design
        5. Sequence-Based Approaches
        6. On-premises
        7. Cloud-based
        8. Hybrid
        9. Pharmaceutical Companies
        10. Biotechnology Companies
        11. CROs & CDMOs
        12. Research Institutes
      12. Benelux
        1. Software
        2. Services
        3. Structure-Based Drug Design
        4. Ligand-Based Drug Design
        5. Sequence-Based Approaches
        6. On-premises
        7. Cloud-based
        8. Hybrid
        9. Pharmaceutical Companies
        10. Biotechnology Companies
        11. CROs & CDMOs
        12. Research Institutes
      13. Rest of Europe
        1. Software
        2. Services
        3. Structure-Based Drug Design
        4. Ligand-Based Drug Design
        5. Sequence-Based Approaches
        6. On-premises
        7. Cloud-based
        8. Hybrid
        9. Pharmaceutical Companies
        10. Biotechnology Companies
        11. CROs & CDMOs
        12. Research Institutes
    3. APAC
      1. APAC Computer Aided Drug Discovery Market By Offering 2025-2034 (USD MILLION/ Units)
        1. Software
        2. Services
      2. APAC Computer Aided Drug Discovery Market By Type 2025-2034 (USD MILLION/ Units)
        1. Structure-Based Drug Design
        2. Ligand-Based Drug Design
        3. Sequence-Based Approaches
      3. APAC Computer Aided Drug Discovery Market By Deployment 2025-2034 (USD MILLION/ Units)
        1. On-premises
        2. Cloud-based
        3. Hybrid
      4. APAC Computer Aided Drug Discovery Market By End User 2025-2034 (USD MILLION/ Units)
        1. Pharmaceutical Companies
        2. Biotechnology Companies
        3. CROs & CDMOs
        4. Research Institutes
      5. China
        1. Software
        2. Services
        3. Structure-Based Drug Design
        4. Ligand-Based Drug Design
        5. Sequence-Based Approaches
        6. On-premises
        7. Cloud-based
        8. Hybrid
        9. Pharmaceutical Companies
        10. Biotechnology Companies
        11. CROs & CDMOs
        12. Research Institutes
      6. Korea
        1. Software
        2. Services
        3. Structure-Based Drug Design
        4. Ligand-Based Drug Design
        5. Sequence-Based Approaches
        6. On-premises
        7. Cloud-based
        8. Hybrid
        9. Pharmaceutical Companies
        10. Biotechnology Companies
        11. CROs & CDMOs
        12. Research Institutes
      7. Japan
        1. Software
        2. Services
        3. Structure-Based Drug Design
        4. Ligand-Based Drug Design
        5. Sequence-Based Approaches
        6. On-premises
        7. Cloud-based
        8. Hybrid
        9. Pharmaceutical Companies
        10. Biotechnology Companies
        11. CROs & CDMOs
        12. Research Institutes
      8. India
        1. Software
        2. Services
        3. Structure-Based Drug Design
        4. Ligand-Based Drug Design
        5. Sequence-Based Approaches
        6. On-premises
        7. Cloud-based
        8. Hybrid
        9. Pharmaceutical Companies
        10. Biotechnology Companies
        11. CROs & CDMOs
        12. Research Institutes
      9. Australia
        1. Software
        2. Services
        3. Structure-Based Drug Design
        4. Ligand-Based Drug Design
        5. Sequence-Based Approaches
        6. On-premises
        7. Cloud-based
        8. Hybrid
        9. Pharmaceutical Companies
        10. Biotechnology Companies
        11. CROs & CDMOs
        12. Research Institutes
      10. Taiwan
        1. Software
        2. Services
        3. Structure-Based Drug Design
        4. Ligand-Based Drug Design
        5. Sequence-Based Approaches
        6. On-premises
        7. Cloud-based
        8. Hybrid
        9. Pharmaceutical Companies
        10. Biotechnology Companies
        11. CROs & CDMOs
        12. Research Institutes
      11. South East Asia
        1. Software
        2. Services
        3. Structure-Based Drug Design
        4. Ligand-Based Drug Design
        5. Sequence-Based Approaches
        6. On-premises
        7. Cloud-based
        8. Hybrid
        9. Pharmaceutical Companies
        10. Biotechnology Companies
        11. CROs & CDMOs
        12. Research Institutes
      12. Rest of Asia-Pacific
        1. Software
        2. Services
        3. Structure-Based Drug Design
        4. Ligand-Based Drug Design
        5. Sequence-Based Approaches
        6. On-premises
        7. Cloud-based
        8. Hybrid
        9. Pharmaceutical Companies
        10. Biotechnology Companies
        11. CROs & CDMOs
        12. Research Institutes
    4. Middle East and Africa
      1. Middle East and Africa Computer Aided Drug Discovery Market By Offering 2025-2034 (USD MILLION/ Units)
        1. Software
        2. Services
      2. Middle East and Africa Computer Aided Drug Discovery Market By Type 2025-2034 (USD MILLION/ Units)
        1. Structure-Based Drug Design
        2. Ligand-Based Drug Design
        3. Sequence-Based Approaches
      3. Middle East and Africa Computer Aided Drug Discovery Market By Deployment 2025-2034 (USD MILLION/ Units)
        1. On-premises
        2. Cloud-based
        3. Hybrid
      4. Middle East and Africa Computer Aided Drug Discovery Market By End User 2025-2034 (USD MILLION/ Units)
        1. Pharmaceutical Companies
        2. Biotechnology Companies
        3. CROs & CDMOs
        4. Research Institutes
      5. UAE
        1. Software
        2. Services
        3. Structure-Based Drug Design
        4. Ligand-Based Drug Design
        5. Sequence-Based Approaches
        6. On-premises
        7. Cloud-based
        8. Hybrid
        9. Pharmaceutical Companies
        10. Biotechnology Companies
        11. CROs & CDMOs
        12. Research Institutes
      6. Turkey
        1. Software
        2. Services
        3. Structure-Based Drug Design
        4. Ligand-Based Drug Design
        5. Sequence-Based Approaches
        6. On-premises
        7. Cloud-based
        8. Hybrid
        9. Pharmaceutical Companies
        10. Biotechnology Companies
        11. CROs & CDMOs
        12. Research Institutes
      7. Saudi Arabia
        1. Software
        2. Services
        3. Structure-Based Drug Design
        4. Ligand-Based Drug Design
        5. Sequence-Based Approaches
        6. On-premises
        7. Cloud-based
        8. Hybrid
        9. Pharmaceutical Companies
        10. Biotechnology Companies
        11. CROs & CDMOs
        12. Research Institutes
      8. South Africa
        1. Software
        2. Services
        3. Structure-Based Drug Design
        4. Ligand-Based Drug Design
        5. Sequence-Based Approaches
        6. On-premises
        7. Cloud-based
        8. Hybrid
        9. Pharmaceutical Companies
        10. Biotechnology Companies
        11. CROs & CDMOs
        12. Research Institutes
      9. Egypt
        1. Software
        2. Services
        3. Structure-Based Drug Design
        4. Ligand-Based Drug Design
        5. Sequence-Based Approaches
        6. On-premises
        7. Cloud-based
        8. Hybrid
        9. Pharmaceutical Companies
        10. Biotechnology Companies
        11. CROs & CDMOs
        12. Research Institutes
      10. Nigeria
        1. Software
        2. Services
        3. Structure-Based Drug Design
        4. Ligand-Based Drug Design
        5. Sequence-Based Approaches
        6. On-premises
        7. Cloud-based
        8. Hybrid
        9. Pharmaceutical Companies
        10. Biotechnology Companies
        11. CROs & CDMOs
        12. Research Institutes
      11. Rest of MEA
        1. Software
        2. Services
        3. Structure-Based Drug Design
        4. Ligand-Based Drug Design
        5. Sequence-Based Approaches
        6. On-premises
        7. Cloud-based
        8. Hybrid
        9. Pharmaceutical Companies
        10. Biotechnology Companies
        11. CROs & CDMOs
        12. Research Institutes
    5. LATAM
      1. LATAM Computer Aided Drug Discovery Market By Offering 2025-2034 (USD MILLION/ Units)
        1. Software
        2. Services
      2. LATAM Computer Aided Drug Discovery Market By Type 2025-2034 (USD MILLION/ Units)
        1. Structure-Based Drug Design
        2. Ligand-Based Drug Design
        3. Sequence-Based Approaches
      3. LATAM Computer Aided Drug Discovery Market By Deployment 2025-2034 (USD MILLION/ Units)
        1. On-premises
        2. Cloud-based
        3. Hybrid
      4. LATAM Computer Aided Drug Discovery Market By End User 2025-2034 (USD MILLION/ Units)
        1. Pharmaceutical Companies
        2. Biotechnology Companies
        3. CROs & CDMOs
        4. Research Institutes
      5. Brazil
        1. Software
        2. Services
        3. Structure-Based Drug Design
        4. Ligand-Based Drug Design
        5. Sequence-Based Approaches
        6. On-premises
        7. Cloud-based
        8. Hybrid
        9. Pharmaceutical Companies
        10. Biotechnology Companies
        11. CROs & CDMOs
        12. Research Institutes
      6. Mexico
        1. Software
        2. Services
        3. Structure-Based Drug Design
        4. Ligand-Based Drug Design
        5. Sequence-Based Approaches
        6. On-premises
        7. Cloud-based
        8. Hybrid
        9. Pharmaceutical Companies
        10. Biotechnology Companies
        11. CROs & CDMOs
        12. Research Institutes
      7. Argentina
        1. Software
        2. Services
        3. Structure-Based Drug Design
        4. Ligand-Based Drug Design
        5. Sequence-Based Approaches
        6. On-premises
        7. Cloud-based
        8. Hybrid
        9. Pharmaceutical Companies
        10. Biotechnology Companies
        11. CROs & CDMOs
        12. Research Institutes
      8. Chile
        1. Software
        2. Services
        3. Structure-Based Drug Design
        4. Ligand-Based Drug Design
        5. Sequence-Based Approaches
        6. On-premises
        7. Cloud-based
        8. Hybrid
        9. Pharmaceutical Companies
        10. Biotechnology Companies
        11. CROs & CDMOs
        12. Research Institutes
      9. Colombia
        1. Software
        2. Services
        3. Structure-Based Drug Design
        4. Ligand-Based Drug Design
        5. Sequence-Based Approaches
        6. On-premises
        7. Cloud-based
        8. Hybrid
        9. Pharmaceutical Companies
        10. Biotechnology Companies
        11. CROs & CDMOs
        12. Research Institutes
      10. Rest of LATAM
        1. Software
        2. Services
        3. Structure-Based Drug Design
        4. Ligand-Based Drug Design
        5. Sequence-Based Approaches
        6. On-premises
        7. Cloud-based
        8. Hybrid
        9. Pharmaceutical Companies
        10. Biotechnology Companies
        11. CROs & CDMOs
        12. Research Institutes
Report Details
−
Trusted by Industry Leaders
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com
custom reports
Need a Tailored Report?
80% of our existing clients ask for tailored reports.
Request Customization

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.